Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma

Lyman, Michelle; Delgado, M.P.

doi:10.1002/cncr.11827

Cited by 169 publications

(135 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

118

Contrasting

Unclassified

Order By: Relevance

“…In agreement with a report by Mayordomo et al (17), 53.7% of all FN events (22/41) occurred during cycle 1. Lyman et al (18) reported that a lack of primary prophylaxis with G-CSF in cycle 1 was associated with an increased risk of FN (18). However, although primary prophylaxis of G-CSF for almost all patients was administered in the present study, the FN occurrence rate in cycle 1 was the highest of all the treatment cycles.…”

Section: Resultscontrasting

confidence: 50%

Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Usami

Kimura

Iwai

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen is considered to be a standard treatment for non-Hodgkin's lymphoma (NHL). Patients receiving CHOP chemotherapy often experience febrile neutropenia (FN) due to myelotoxicity. The proper management of FN is essential to guarantee a positive outcome of the NHL treatment. Therefore, the present study retrospectively examined chemotherapy continuity and the incidence of FN during CHOP therapy in an outpatient setting. The subjects were 136 patients who received CHOP chemotherapy between January 2012 and December 2014. A total of 31 patients unable to be treated in an outpatient setting were excluded from the study. Of the remaining 105 patients, 73 patients who did not require hospitalization during the chemotherapy treatment were included in the non-hospitalized group, and 32 patients who required hospitalization during chemotherapy treatment were included in the re-hospitalization group. The numbers of patients from these two groups who completed the planned treatment were 71 and 24, respectively (P<0.01). In addition, the duration of granulocyte-colony stimulating factor (G-CSF) treatment was 5.3±1.22 and 6.1±1.46 days, respectively (P<0.01). The numbers of patients experiencing FN in an outpatient setting were 14 and 19, respectively (P<0.01). During administration of primary prophylaxis with G-CSF, the incidence of FN was 21.0% (22/105) in cycle 1. In conclusion, the present study has revealed a requirement to educate patients about infection prevention prior to the first cycle of chemotherapy. Patients who require the administration of long-term G-CSF are at risk of unplanned re-hospitalization, and treating them with polyethylene glycol G-CSF to reduce the number of required injections should be considered as an option. Therefore, proper supportive therapy and management of infection are important to safely treat patients with CHOP in an outpatient setting.

show abstract

Section: Resultscontrasting

confidence: 50%

Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Usami

Kimura

Iwai

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…14 Similar findings have been reported from a retrospective analysis of patients with non-Hodgkin lymphoma in which the receipt of Ն 80% of the intended dose was associated significantly with an increase in complete response rates. 39 Furthermore, hospitalization for febrile neutropenia during the first cycle of chemotherapy, when NH often occurs, 8 has been associated with an increased risk of early termination of the chemotherapy, 10 thus preventing patients from receiving the benefit of a full course of treatment.…”

Section: Discussionmentioning

confidence: 99%

Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

Caggiano

Weiss²,

Rickert³

et al. 2005

Cancer

296

219

View full text Add to dashboard Cite

BACKGROUNDNeutropenia is a common side effect of chemotherapy, often requiring hospitalization for treatment of severe cases. Neutropenia hospitalization (NH) rates have been reported in individual studies, but national estimates are needed.METHODSChemotherapy‐induced NHs were identified in the 1999 hospital discharge data bases from 7 states. Cancer and chemotherapy prevalence data from the National Cancer Institute's Surveillance, Epidemiology, and End Results Program and the National Cancer Data Base were used to calculate national NH rates for 13 cancer types. NH cost was estimated by multiplying charges by institution‐specific, cost‐to‐charge ratios from the 1999 Centers for Medicare and Medicaid Services Hospital Cost Report. NH incidence was projected to national levels using population data from the United States Census and the Centers for Disease Control and Prevention.RESULTSThere were 20,780 discharges with documentation of cancer, chemotherapy, and neutropenia identified. Projecting to national levels, NH incidence was estimated at 60,294 cases (7.83 cases per 1000 cancer patients). The mean NH cost was $13,372. The mortality rate among patients with NH was estimated at 6.8% or 1 death for every 14 hospitalized patients. Among 13 selected cancer types, the NH rate was 34.20 cases per 1000 patients receiving chemotherapy (1 in 29 patients). NH was particularly common in patients with hematologic tumors, with an incidence of 43.3 cases per 1000 patients with such tumors (1 in 23 patients). The average NH cost for hematologic malignancies was $20,400, more than double the cost of NH for solid tumors.CONCLUSIONSAccording to the current study, NH affects > 60,000 patients with cancer each year in the United States, with an average cost of $13,372 per hospitalization and an associated inpatient mortality rate of 6.8%. Cancer 2005. © 2005 American Cancer Society.

show abstract

“…The probability of developing neutropenia varies for each individual regimen; currently, predictions are based on the treatment regimen used and the experience of the attending physician (Sato et al, 2012 anticancer drugs (Lyman and Delgado, 2003;Millward et al, 2003;Timmer-Bonte et al, 2005). By contrast, few investigations have examined the predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with CRPC.…”

Section: Predictive Factors For Neutropenia After Docetaxel-based Sysmentioning

confidence: 99%

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Kwon¹,

Oh²,

Lee³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The aim of this study was to determine predictive factors for neutropenia after docetaxel-based systemic chemotherapy in patients with castration-resistant prostate cancer (CRPC). The study included 40 Korean CRPC patients who were treated with several cycles of docetaxel plus prednisolone from May 2005 to May 2012. Patients were evaluated for neutropenia risk factors and for the incidence of neutropenia. In this study, nine out of forty patients (22.5%) developed neutropenia during the first cycle of docetaxel-based systemic chemotherapy. Four experienced grade 2, three grade 3, and one grade 4 neutropenia. Multivariate analysis showed that pretreatment white blood cell (WBC) count (p=0.042), pretreatment neutrophil count (p=0.015), pretreatment serum creatinine level (p=0.027), and pretreatment serum albumin level (p=0.017) were significant predictive factors for neutropenia. In conclusion, pretreatment WBC counts, neutrophil counts, serum creatinine levels, and serum albumin levels proved to be significant independent risk factors for the development of neutropenia induced by docetaxel-based systemic chemotherapy in patients with CRPC.

show abstract

Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP‐R, or CNOP chemotherapy for intermediate‐grade non‐Hodgkin lymphoma

Cited by 169 publications

References 15 publications

Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting

Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer

Contact Info

Product

Resources

About